The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Highlights from WCLC 2018: NELSON, ALTA, IMpower133 & PACIFIC
Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives an update on the key data from the World Conference on Lung Cancer 2018. Prof. Reck emphasizes the importance of the likely policy-changing NELSON trial (ISRCTN63545820), which provided strong evidence for low-dose CT screening for lung cancer in Europe. He also covers: the ALTA trial (NCT02094573; brigatinib for ALK positive non-small cell lung cancer patients previously treated with crizotinib), the IMpower133 trial (NCT02763579; atezolizumab, carboplatin and etoposide for small cell lung cancer) and the PACIFIC trial (NCT02125461; durvalumab plus chemoradiation). This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
